Global Pharmaceuticals & Biotech Top Stock Picks from Analysts

Neurogene

Market Cap: US$279.9m

A clinical stage biotechnology company, develops genetic medicines for rare neurological diseases.

Hansa Biopharma

Market Cap: SEK 2.6b

A biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe.

DiaMedica Therapeutics

Market Cap: US$277.6m

A clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases.

Mereo BioPharma Group

Market Cap: US$275.2m

A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.

Vanda Pharmaceuticals

Market Cap: US$274.2m

A biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.

Lineage Cell Therapeutics

Market Cap: US$274.0m

A clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally.

Capricor Therapeutics

Market Cap: US$271.6m

A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.

Candel Therapeutics

Market Cap: US$268.7m

A clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients.

Lexeo Therapeutics

Market Cap: US$268.4m

A clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States.

Formosa Laboratories

Market Cap: NT$8.2b

Manufactures and sells active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally.

Crescent Biopharma

Market Cap: US$267.6m

An oncology company, develops therapies for cancer patients.

Atea Pharmaceuticals

Market Cap: US$264.3m

A clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections.

Neumora Therapeutics

Market Cap: US$264.0m

A clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States.

Korro Bio

Market Cap: US$263.7m

A biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States.

Perspective Therapeutics

Market Cap: US$262.9m

Develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.

Cartesian Therapeutics

Market Cap: US$260.0m

A clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases.

TriSalus Life Sciences

Market Cap: US$256.8m

Engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers.

High Tide

Market Cap: CA$355.7m

Engages in the cannabis retail business in Canada.

enGene Holdings

Market Cap: US$255.5m

Through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer.

Fennec Pharmaceuticals

Market Cap: US$255.5m

Operates as a commercial stage biopharmaceutical company in the United States.

Jade Biosciences

Market Cap: US$253.8m

Operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.

ProQR Therapeutics

Market Cap: US$251.8m

A biotechnology company, focuses on the discovery and development of novel therapeutic medicines.

Transcenta Holding

Market Cap: HK$2.0b

A clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs for unmet medical needs in the People’s Republic of China and the United States.

Silence Therapeutics

Market Cap: US$247.0m

A biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.

Allogene Therapeutics

Market Cap: US$246.3m

A clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.

Oryzon Genomics

Market Cap: €208.9m

A clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders.

Tenax Therapeutics

Market Cap: US$239.9m

A clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.

Monopar Therapeutics

Market Cap: US$239.6m

A clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.

Annexon

Market Cap: US$236.3m

A clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.

Sagimet Biosciences

Market Cap: US$235.8m

A clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States.

Newron Pharmaceuticals

Market Cap: CHF 185.8m

A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.

Santhera Pharmaceuticals Holding

Market Cap: CHF 184.7m

A specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia.

Humacyte

Market Cap: US$231.2m

Engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.

Tonix Pharmaceuticals Holding

Market Cap: US$230.6m

A biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease.

BioVersys

Market Cap: CHF 184.0m

A clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria.

Immuneering

Market Cap: US$227.0m

A clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients.